MHC vs. NCYT, POLX, IHC, AVO, RUA, SUN, BELL, DEMG, NIOX, and SN
Should you be buying MyHealthChecked stock or one of its competitors? The main competitors of MyHealthChecked include Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), and Smith & Nephew (SN). These companies are all part of the "medical devices" industry.
MyHealthChecked vs.
Novacyt (LON:NCYT) and MyHealthChecked (LON:MHC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
MyHealthChecked has lower revenue, but higher earnings than Novacyt. MyHealthChecked is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks.
In the previous week, Novacyt had 1 more articles in the media than MyHealthChecked. MarketBeat recorded 1 mentions for Novacyt and 0 mentions for MyHealthChecked. Novacyt's average media sentiment score of 0.76 beat MyHealthChecked's score of 0.00 indicating that Novacyt is being referred to more favorably in the media.
Novacyt has a beta of -1.86, indicating that its share price is 286% less volatile than the S&P 500. Comparatively, MyHealthChecked has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500.
0.1% of Novacyt shares are held by institutional investors. Comparatively, 3.1% of MyHealthChecked shares are held by institutional investors. 3.1% of Novacyt shares are held by insiders. Comparatively, 53.6% of MyHealthChecked shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Novacyt received 36 more outperform votes than MyHealthChecked when rated by MarketBeat users.
MyHealthChecked has a net margin of -11.06% compared to Novacyt's net margin of -203.06%. MyHealthChecked's return on equity of -12.80% beat Novacyt's return on equity.
Summary
MyHealthChecked beats Novacyt on 8 of the 14 factors compared between the two stocks.
Get MyHealthChecked News Delivered to You Automatically
Sign up to receive the latest news and ratings for MHC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MyHealthChecked Competitors List
Related Companies and Tools
This page (LON:MHC) was last updated on 2/22/2025 by MarketBeat.com Staff
